Berlin Cures BC 007 –
Clinical Development Status Update.
Berlin Cures plans to conduct a large international study with the goal of obtaining accelerated approval of BC 007 for the treatment of Long Covid Syndrome.
A new batch of BC 007 is currently being manufactured to conduct clinical trials in the indication of Long Covid Syndrome. Berlin Cures plans to conduct a multicenter, multinational, double-blind, randomized study with the goal of achieving accelerated approval for BC 007 in Long Covid syndrome in coordination with the relevant international regulatory authorities. Our partner in conducting this study is Parexel International. The study is expected to take place at more than 15 centers in Germany, Switzerland, the Netherlands, Spain, and Finland. The study is scheduled to start in the summer of 2022.
The list of participating centers will be published in due course. Berlin Cures itself cannot select or pre-register patients for study participation.
We ask all patients interested in participating in the study to contact one of the study centers, as soon as the list of participating sites is published. We kindly ask to refrain from inquiries by phone with us.